DBV Technologies (NASDAQ:DBVT) Trading 8.4% Higher – Should You Buy?

DBV Technologies S.A. (NASDAQ:DBVT) traded up 8.4% on Monday . The company traded as high as $14.49 and last traded at $14.61. Approximately 374,754 shares were traded during trading, an increase of 22% from the average session volume of 307,907 shares. The stock had previously closed at $13.48.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DBVT shares. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Citizens Jmp increased their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Weiss Ratings lowered shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Finally, Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Price Performance

The firm has a market capitalization of $846.55 million, a PE ratio of -4.07 and a beta of -0.93. The firm’s fifty day moving average is $15.41 and its two-hundred day moving average is $18.90.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.90 million. DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%. As a group, equities research analysts predict that DBV Technologies S.A. will post -2.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Diversify Wealth Management LLC purchased a new stake in DBV Technologies during the first quarter valued at about $1,293,000. Dorsey Wright & Associates bought a new position in DBV Technologies in the 1st quarter worth about $2,142,000. Elmind Capital LP purchased a new position in DBV Technologies during the first quarter valued at approximately $5,536,000. UBS Group AG boosted its stake in DBV Technologies by 165,347.3% during the fourth quarter. UBS Group AG now owns 244,862 shares of the company’s stock valued at $4,694,000 after buying an additional 244,714 shares during the period. Finally, Perceptive Advisors LLC purchased a new position in shares of DBV Technologies during the first quarter worth about $20,146,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.